AT-278 is under clinical development by Arecor Therapeutics and currently in Phase I for Type 2 Diabetes. According to GlobalData, Phase I drugs for Type 2 Diabetes have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AT-278’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AT-278 overview
AT-278 is under development for the treatment of type 1 diabetes (Juvenile diabetes) and type 2 diabetes. The drug candidate acts by targeting the insulin receptor. It is an Ultra concentrated rapid acting insulin. The drug candidate is delivered as a switch from intravenous infusion to subcutaneous delivery as a liquid composition. The drug candidate is developed based on Arestat formulation technology platform.
Arecor Therapeutics overview
Arecor Therapeutics (Arecor) is a biopharmaceutical company that discovers and develops treatments for chronic diseases. It is investigating AT247, an ultra-rapid acting insulin to treat type 1 and type 2 diabetes; AT278, an ultra-concentrated rapid acting insulin targeting insulin resistant diabetic patients; AT299 program against diabetes. The company is also evaluating AT292 to treat alpha-1 antitrypsin deficiency; formulations and biosimilars in partnership with pharmaceutical and biotechnology companies. It utilizes its proprietary formulation technology platform Arestat, to develop and deliver its products by allowing control of protein behavior under various stress conditions. Arecor is headquartered in Saffron Walden, Essex, the UK.
For a complete picture of AT-278’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
